irasia.com - Investor Relations Asia Pacific
HOME

WuXi Biologics (Cayman) Inc.
(Incorporated in the Cayman Islands with limited liability)

Press Releases       


Please download the latest "Acrobat Reader" to view the PDF.

  • 2021-August-23
  • WuXi Biologics 2021 Interim Results, Revenue Increases by 126.7% Y-o-Y to RMB4,406.8 Million, Gross Profit Grows by 191.7% Y-o-Y to RMB2,296.8 Million, Adjusted Net Profit Attributable to Owners of the Company Increases by 163.0% Y-o-Y to RMB1,768.7 Million, Gross and Net Profit Margins Reach 52.1% and 42.7%, Respectively, Diluted EPS Reaches RMB0.42 with 133.3% Growth Y-o-Y (in PDF)
  • 2021-March-23
  • 2020 Results Record High Despite a Challenging Year, Revenue Increased by 40.9% Y-o-Y to RMB5,612 Million, Gross Profit Rose by 52.7% Y-o-Y to RMB2,533 Million, Net Profit Grew by 67.5% Y-o-Y to RMB1,693 Million, Record-high Gross Margin of 45.1% and Net Profit Margin of 30.2%, Milestone Revenue Surged by 71.7% to US$95 Million, Total Backlog up 122.0% to US$11,324 Million (in PDF)
  • 2022
  • 2022 Press Releases
  • 2020
  • 2020 Press Releases
  • 2019
  • 2019 Press Releases
  • 2018
  • 2018 Press Releases
  • 2017
  • 2017 Press Releases


  • Company's Index
  • irasia.com

  • About irasia.com   |   Terms of Use   |   Privacy Policy Statement   |   Disclaimer
    © Copyright 1996-2024 irasia.com Ltd. All rights reserved.
    DISCLAIMER:
    irasia.com Ltd. makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd. be liable for damages resulting from the use of the information provided on this website.
    Cookie Policy

    This website uses cookies. Please refer to our Cookie Notice and Privacy Notice for further information. By continuing to use this website, you agree to our use of cookies.

    Close